Supplemental Table 1: Characteristics for patients admitted with COVID-19 during March 1 to May 31, 2020

|  |  |
| --- | --- |
|    | n=829 |
| Sex, male n (%)  | 410 (49.5) |
| Age, years (SD)  | 64.9 (17.9) |
| Race      White      Black      Hispanic      Asian/Pacific Islander      Other      Unknown  | 314 (37.9)208 (25.1)151 (18.2)41 (4.9)38 (4.6)77 (9.3) |
| Comorbid conditions, n (%)      Diabetes mellitus       Hypertension      Obesity      Congestive heart failure      Chronic obstructive pulmonary disorder      End stage renal disease      Human immunodeficiency virus  | 341 (41.1)330 (39.8)161 (19.4)159 (19.2)84 (10.1)54 (6.5)2 (0.2) |
| Hospital admission in last 90 days, n (%)  | 112 (13.5) |
| **Events after admission**  |  |
| Length of stay, days median (IQR)  | 6 (2-13) |
| Endotracheal intubation, n (%)  | 133 (16.0) |
| Prescribed any antibiotic listed below, n (%)      Ceftriaxone      Vancomycin or linezolid      Anti-pseudomonal beta-lactam       Azithromycin      Levofloxacin  | 607 (73.2)415 (50.0)273 (32.9)262 (31.6)262 (31.6)40 (4.8) |
| Respiratory culture obtained, n (%)      Endotracheal aspirate      Expectorated sputum      Bronchoalveolar lavage  | 196 (23.6)176 (21.2)34 (4.1)13 (1.6) |
| Positive respiratory culture, n (%)      Community-acquired bacteria      Hospital-acquired bacteria\*  | 73 (8.8)15 (1.8)58 (9.7) |
| Microbiology from 567 respiratory cultures, n (%)      Enterobacterales      *Pseudomonas aeruginosa* *Staphylococcus aureus* *Streptococcus* species     *Haemophilus influenzae* *Moraxella catarrhalis*      Commensal respiratory flora      Yeast      No growth   | 76 (13.4)43 (7.6)75 (13.2)4 (0.7)3 (5.3)1 (0.2)176 (31.0)137 (16.5)46 (8.1) |
| *C. difficile* polymerase chain reaction positive   | 29 (3.5) |
| Inpatient mortality or discharge to hospice  | 171 (20.6) |

\* Out of 601 encounters with a hospital length of stay of at least 4 days

Supplemental Table 2: Antibiotic utilization per 1000 patient-days of therapy for patients with COVID-19 compared to total hospital census from March 1 to May 31 2018, 2019, and 2020

|  |  |  |  |
| --- | --- | --- | --- |
|    | 2020 | 2019 | 2018 |
| Total hospital days  | -- | 54394 | 63507 | 62641 |
|    | COVID-19 DOT/1000 | Average DOT/1000 patient days |
| Total of all below agents   | 831.9 | 368.3 | 281.7 | 274.7 |
| Vancomycin   | 190.8 | 74.9 | 50.9 | 57.5 |
| Ceftriaxone   | 184.1 | 102.7 | 72.8 | 67.5 |
| Cefepime   | 170.2 | 79.0 | 62.7 | 58.0 |
| Azithromycin   | 97.5 | 18.4 | 13.8 | 15.0 |
| Ceftazidime   | 67.5 | 21.5 | 14.2 | 15.9 |
| Meropenem   | 64.4 | 28.7 | 22.4 | 17.7 |
| Levofloxacin   | 23.1 | 7.9 | 9.6 | 8.4 |
| Piperacillin/tazobactam   | 22.9 | 30.3 | 32.2 | 31.5 |
| Linezolid   | 11.4 | 4.8 | 3.1 | 3.1 |